Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$5.04
-3.4%		$5.91
$3.98
▼
$13.69
$32.60M2.3458,350 shs28,021 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.28
-8.6%		$0.97
$0.74
▼
$1.74
$44.02M0.05150,394 shs301,505 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
$13.48
$15.15
▼
$28.77
$10.13M1.6229,886 shsN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.30
+2.1%		$6.11
$8.50
▼
$23.00
$39.40MN/A37,647 shs4,558 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-3.45%-18.84%-26.85%+1.00%-50.59%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-8.57%+24.27%+23.08%+30.61%-21.47%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%0.00%0.00%+1.29%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-8.01%+8.27%-14.27%-49.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$5.04
-3.4%		$5.91
$3.98
▼
$13.69
$32.60M2.3458,350 shs28,021 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.28
-8.6%		$0.97
$0.74
▼
$1.74
$44.02M0.05150,394 shs301,505 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
$13.48
$15.15
▼
$28.77
$10.13M1.6229,886 shsN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.30
+2.1%		$6.11
$8.50
▼
$23.00
$39.40MN/A37,647 shs4,558 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-3.45%-18.84%-26.85%+1.00%-50.59%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-8.57%+24.27%+23.08%+30.61%-21.47%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%0.00%0.00%+1.29%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-8.01%+8.27%-14.27%-49.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
2.86
Moderate Buy$38.50663.89% Upside
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00290.63% Upside
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00
N/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GLYC, IZTC, ATNM, and ALGS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/10/2026
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/28/2026
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/10/2026
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/25/2026
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$31.52M1.00N/AN/A$8.67 per share0.58
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M1.15N/AN/A$1.31 per share0.98
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,013.15N/AN/A$0.08 per share1.96
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$24.19M-$7.30N/AN/AN/A-241.01%-160.72%-92.30%11/5/2026 (Estimated)
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest GLYC, IZTC, ATNM, and ALGS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$1.09-$0.14+$0.95-$0.14$24.68 million$27.78 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/A
2.19
2.19
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
60.43%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
7.80%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
8.70%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
906.25 million5.76 millionNo Data
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.44 million29.32 millionOptionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionNo Data
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A

Recent News About These Companies

Invizyne Technologies (NASDAQ:IZTC) Trading Down 7.9% - Time to Sell?
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31014040
Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)
February 13, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/institutional-investors-own-significant-stake-122811776.html
What’s in a Name: Out with Invizyne, In with eXoZymes
February 12, 2025  |  genengnews.comG
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ
February 11, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-rebrands-as-exozymes-with-new-ticker-exoz/ar-AA1yLfmv
Invizyne announces corporate name change to eXoZymes
February 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-announces-corporate-name-change-to-exozymes-1034336391
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%
February 4, 2025  |  aaii.comA
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%
January 30, 2025  |  aaii.comA
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock
January 21, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-ceo-michael-heltzen-buys-20-345-in-stock/ar-AA1xAdEg
Invizyne Technologies Inc trading resumes
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-resumes-1034183742
Invizyne Technologies Inc trading halted, volatility trading pause
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-halted-volatility-trading-pause-1034183743
Michael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) Stock
November 20, 2024  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-iztc-insider-buying-and-selling-2024-11-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aligos Therapeutics stock logo

Aligos Therapeutics NASDAQ:ALGS

$5.04 -0.18 (-3.45%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$5.09 +0.05 (+1.01%)
As of 04:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.28 -0.12 (-8.57%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$1.28 +0.00 (+0.39%)
As of 09/14/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$6.30 +0.13 (+2.13%)
As of 09/11/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas